With The Markets Getting Pounded, Nasdaq Idea (INM) Maintains Today's Early Green Pace (See Why)

Here's why INM continues to be a good story to research going into the end of this week. With The Markets Getting Pounded, Nasdaq Idea (INM) Maintains Today's Early Green Pace (See Why) [Yahoo Finance]( Reports Fewer Than 4Mn Shares In Float! March 16th Dear Reader, Here's why INM continues to be a good story to research going into the end of this week. If you haven't been paying, the markets have been getting crushed. Red, red, and more red. But, do you see what's not in the red today? INM. Part of the reason is INM could be [building strong support]( recently at its 5-Day Simple Moving Average and its 5-Day Exponential Moving Average (both of which it's trading above currently). If more support grows at those levels, it could look to prop INM up to try and run down previous highs (like when it was trading at over $2.00+ last month). Get INM pulled up right now and have it pinned to the top of your watch-list to close this week out. ----- We've got a past champ back on alert. Brought to your attention previously, all it did was run from a November 16th open of $3.14 to a high of $4.75 that same session. With a $1.50+ run under its belt, it produced an intraday surge of approximately 51%. Not bad, but that's just the tip of the iceberg. This company is looking to disrupt a potential [$1.5Bn Epidermolysis bullosa market]( with its treatment currently in a phase 2 clinical trial. And with a low float of fewer than 4Mn shares, closing 2022 in a strong cash position to achieve 2023 milestones, publishing a peer-reviewed study in the International Journal of Molecular Sciences, and key oversold technicals signaling the potential for a reversal/bounce, the near term couldn't be brighter for this Nasdaq breakout idea. Drop everything to get this past champ pulled up for Thursday, March 16th's, opening bell: *InMed Pharmaceuticals Inc. (INM)* InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cann-a-binoids and cann-a-binoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. And right now based on several potential breakout catalysts, INM requires your immediate focus. Check them out: No. 1 - A Stunningly Low Float Could Lead To Extreme Volatility No. 2 - Key Update Details Regarding Company's Strong Pipeline Of Programs No. 3 - Published Peer Review Study Demonstrate The Anti-inflammatory Effects Of Rare Cann-a-binoids No. 4 - Neurodegenerative Disease Program Advances With Help From NSERC Grant Funding No. 5 - Could Oversold Leaning Technicals Signal Significant Bounce/Reversal Potential? But more on those in a second... InMed's Pharmaceutical Development Of Rare Cann-a-binoids InMed is developing a pipeline of rare cann-a-binoids across a spectrum of therapeutic applications with large unmet medical needs. The company's pharmaceutical programs include a Phase 2 clinical trial studying the safety and efficacy of cann-a-binol (CBN) cream for epidermolysis bullosa and preclinical programs in glaucoma and neurodegenerative disease. InMed is the first company to advance CBN into a Phase 2 clinical trial. The Phase 2 clinical trial in treatment of EB (Dermatology) is about to conclude enrollment this month with data read out expected in a few months. CBN is the active pharmaceutical ingredient in two of our pharmaceutical development programs – INM-755 cann-a-binol cream, in Phase 2 clinical development for epidermolysis bullosa, and INM-088 CBN eye drops in preclinical development for glaucoma. CBN is one of several rare cann-a-binoids found in the Cann-a-bis plant at significantly lower levels relative to the more commonly T-H-C and C-B-D. InMed is exploring the unique physiological effects of CBN, as well as other rare cann-a-binoids, and their therapeutic potential to treat disease. A Growing Library Of New Cann-a-binoid Analogs InMed’s division, BayMedica, has produced an extensive library of cann-a-binoid new chemical entities for pharmaceutical development, aimed at targeting diverse clinical indications. Years of cann-a-binoid research and knowledge has led to a myriad of patentable cann-a-binoid analogs. Its analog patents offer broad protection through its unique molecular components, such as side-chain structures. These cann-a-binoid analogs are suitable for pharmaceutical development. Rare Cann-a-binoids As Raw Ingredients For The Health And Wellness Industry InMed’s subsidiary, BayMedica, is manufacturing rare cann-a-binoids for the health and wellness industry. BayMedica is the leading large batch supplier of cannabichromene (CBC) and has recently launched sales of cannabidivarin (CB-DV) and ultra-rare cann-a-binoid, cannabicitran (CBT). Commercial production of tetra-hydro-cannabivarin (TH-CV) is underway and is expected to be available for commercial wholesale soon. A Diverse Patent Portfolio InMed has a strong patent position that includes 13 patent families covering manufacturing, methods of use and formulation of rare cann-a-binoids. The company's portfolio includes a broad patent application for the creation of several variations of novel cann-a-binoid compounds, biosynthetic pathway and semi-synthetic production of both natural cann-a-binoids and analogs, methods for manufacturing and uses of specific rare cann-a-binoids. Research Partnerships That Strengthen The Company's Cann-a-binoid Knowledge InMed's collaborations with cann-a-binoid experts from around the world ensure we stay at the forefront of rare cann-a-binoid research and development. Their partners play a key role in the development of their programs and share in their pursuit of understanding the biological activity and therapeutic relevance of rare cann-a-binoids and demonstrating the preclinical and clinical evidence that will allow for its safe use. InMed's Product Pipeline [Company Website.]( [Company Presentation.]( ----- And as I mentioned above, INM has several potential breakout catalysts to familiarize yourself with ASAP. Here they are: No. 1 INM Potential Catalyst - A Stunningly Low Float Could Lead To Extreme Volatility According to the [Yahoo Finance website]( INM has a low float. The website reports this profile to have approximately 3.31Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. With so few shares available, the potential for volatility rises (when considering the size of a profile's float). Could more 2023 positive company news help provide a near term spark? ----- No. 2 INM Potential Catalyst - Key Update Details Regarding Company's Strong Pipeline Of Programs InMed Reports Second Quarter Fiscal 2023 Fi-nan-cial Results and Provides Business Update - Closed calendar year 2022 with strong cash position of $11.5Mn - Approaches completion of enrollment for Ph 2 clinical trial in EB - Advances research using rare cann-a-binoids in treating glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), ..., today announced fi-nan-cial results for the second quarter of fiscal year 2023 which ended December 31, 2022. ... “This period was another strong operational quarter for the Company as we advanced our pharmaceutical programs, including the launch of INM-900 series compounds for the evaluation of neurodegenerative diseases. We are currently approaching the end of enrollment in our Ph 2 clinical trial in Epidermolysis Bullosa (“EB”). As we move into calendar 2023, we have a strong pipeline of programs at various stages of development,” said Eric A. Adams, President and CEO of InMed. “Fiscal Q2 saw significant cost savings across the different business segments resulting in a reduced cash burn. In addition, our strong cash position of over $11Mn enables us to pursue several material milestones throughout calendar 2023.” Business update Pharmaceutical Development Programs INM-755 – Phase 2 Clinical Trial in EB To date, the Ph 2 clinical trial has enrolled 17 patients of its targeted 20 patients. Several additional prospective patients have been identified for screening at the clinical sites and enrollment is expected to complete at the end of March 2023, with initial read out expected in early calendar 3Q 2023. INM-088 – Glaucoma Program The Company continues to conduct the required IND enabling preclinical testing and has planned GLP toxicology studies in mid-2023. Human clinical trials remain on track to commence in calendar 2024. INM-900 – Neurodegenerative Diseases Program Two cann-a-binoid analogs are being assessed in in vivo models of neurodegenerative diseases and the Company expects these studies to be completed and a candidate selected for further development in calendar 2Q 2023. Our research demonstrated the neuroprotective effects of specific cann-a-binoid analogs and their potential to improve neuronal function. BayMedica Commercial Business BayMedica continues to be a leading producer of cann-a-bichromene (CBC) with increased revenue in the last two quarters, including a 46% quarter over quarter increase in fiscal 2Q 2023. Management continues to evaluate strategic options and long-term supply agreements for this business segment. ... [Read the full article here.]( ----- No. 3 INM Potential Catalyst - Published Peer Review Study Demonstrate The Anti-inflammatory Effects Of Rare Cann-a-binoids InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cann-a-binoids in Skin Conditions Supports the therapeutic potential of rare cann-a-binoids in inflammatory skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne Further demonstrates the anti-inflammatory effects of CBC, TH-CV, CBG and CB-GA Details possible mechanisms of action on how rare cann-a-binoids can interact with specific skin-related endocann-a-binoid receptors Vancouver, British Columbia--(Newsfile Corp. - March 13, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), ..., today announced that a peer-reviewed scientific study entitled "Rare phytocann-a-binoids exert anti-inflammatory effects on human keratinocytes via the endocann-a-binoid system and MAPK signalling pathway" has been published in the International Journal of Molecular Sciences. This is the second such Company-sponsored study to demonstrate the anti-inflammatory effects of rare cann-a-binoids and their potential application for the treatment of skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne. The study, conducted in collaboration with Dr. Mauro Maccarrone at the Università degli Studi dell'Aquila, investigates the anti-inflammatory effects of the rare cann-a-binoids, canna-bichromene (CBC), Δ-9-tetra-hydro-canna-bivarin (TH-CV), canna-bigerol (CBG) and canna-bigerolic acid (CB-GA) on inflamed human keratinocytes (HaCaT cells) and elucidates the potential mechanism of action associated with these compounds in the skin. Results demonstrate these rare cann-a-binoids significantly blocked inflammation by reducing the release of tested pro-inflammatory interleukins, including IL-1β, IL-8, IL-12, IL-31, IL-10 and tumor necrosis factor (TNF-β). Results showed that TH-CV and CB-GA act synergistically with the endocann-a-binoid system elements to activate anti-inflammatory effects. This demonstration of the mechanism of action opens new perspectives for possible treatments of inflammation-related skin conditions. "This study provides further evidence of the ability of rare cann-a-binoids to exert anti-inflammatory effects in human keratinocytes through modifications of the endocann-a-binoid system and MAPK signalling," said InMed's scientific advisor, Dr. Mauro Maccarrone, Professor and Chair of Biochemistry at the Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy. "Results from this study demonstrate important mechanisms of biological effects of rare cann-a-binoids and support the therapeutic potential of TH-CV and CB-GA on inflammation-related skin conditions." "Research into the biological activity of the rare cann-a-binoids has been limited to date and InMed continues to support this foundational research to further understand the pharmacological properties of these rare cann-a-binoids," said Dr. Eric Hsu, Senior VP, Preclinical Research and Development. "As we continue to build our pipeline of rare cann-a-binoid and cann-a-binoid analog therapeutics, evidence demonstrating the specific biological activity will be key in the selection and advancement of our programs." ... [Read the full article here.]( ----- No. 4 INM Potential Catalyst - Neurodegenerative Disease Program Advances With Help From NSERC Grant Funding InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding - Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s - Identified two lead cann-a-binoid analog compounds for in vivo studies - NSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar from University of British Columbia (UBC) VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), ..., today announces the launch of its neurodegenerative disease program (INM-900 series), which will be investigating the effects of cann-a-binoid analogs in diseases such as Alzheimer’s, Huntington’s and Parkinson’s. In research conducted to date, InMed has identified two cann-a-binoid analogs demonstrating promising effects related to the treatment of neurodegenerative diseases, warranting further investigation in in vivo studies. InMed will be conducting studies using in vivo models in neurodegenerative disease to select the most appropriate candidate for clinical studies. Early preclinical efficacy readout is expected in 2Q 2023. In addition, Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences at UBC has been awarded an Alliance grant from NSERC, with InMed as the named industry partner. The funding will support the research and development studies of InMed’s cann-a-binoid pharmaceutical candidates, investigating their potential therapeutic effects in neurodegenerative diseases. The collaboration project is entitled “Pharmacological characterization of phytocann-a-binoids and the endocann-a-binoid system.” InMed's Senior Vice President of Preclinical Research & Development, Eric Hsu, Ph.D., commented, "We are pleased that our efforts have led to the identification of two cann-a-binoid analog candidates to advance to in vivo studies. Our team will continue this important research in neurodegenerative diseases under the NSERC Alliance grant. Our early studies are showing promising neuroprotective effects as well as neurite outgrowth, signifying the potential to enhance neuronal function that may be important in the treatment of neurodegenerative diseases. This program, in conjunction with the work we are doing within glaucoma, increases our focus on, and expands our pipeline within, the neuroprotection space.” In December 2021, InMed filed an international patent application demonstrating neuroprotection and enhanced neuronal function using rare cann-a-binoids and analogs for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others. The patent specifies such compounds that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection in a population of affected neurons. ... [Read the full article here.]( ----- No. 5 INM Potential Catalyst - Could Oversold Leaning Technicals Signal Significant Bounce/Reversal Potential? As of 2:00PM EST Wednesday, Barchart was reporting this profile to have several oversold leaning technicals. These technicals could be signaling a healthy reversal could be approaching in the near term. Here's the definition of a "reversal" from [Investopedia]( "A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart." Now, here are [some key technicals]( (as of 2:00PM EST Wednesday) that could signal INM to be leaning oversold and on the verge of a potential reversal. - 9-Day Relative Strength Index: 32.53% - 14-Day Relative Strength Index: 33.56% When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued. - 14-Day Raw Stochastic: 26.92% - 14-Day Williams %R: 73.08% As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued. Keep an eye on these technicals closely. ----- INM Recap - Multiple Potential Catalysts Could Lead To A Breakout Spark No. 1 - A Stunningly Low Float Could Lead To Extreme Volatility No. 2 - Key Update Details Regarding Company's Strong Pipeline Of Programs No. 3 - Published Peer Review Study Demonstrate The Anti-inflammatory Effects Of Rare Cann-a-binoids No. 4 - Neurodegenerative Disease Program Advances With Help From NSERC Grant Funding No. 5 - Could Oversold Leaning Technicals Signal Significant Bounce/Reversal Potential? ----- Coverage is officially reinitiated on INM. When time permits, do this: Get INM on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 4/21/22 and ending on 4/22/22 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid thirty thousand USD via bank wire transfer. We own zero shares of (INM). Pursuant to an agreement between SWN Media LLC and TD Media LLC, StockWireNews has been hired for a period beginning on 6/9/22 and ending on 6/10/22 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (INM). Pursuant to an agreement between SWN Media LLC and North Equities Corp., FierceInvestor (FI) has been hired for a period beginning on 11/15/22 and ending on 11/16/22 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (INM). Pursuant to an agreement between SWN Media LLC and InMed Pharmaceuticals Inc., FierceInvestor (FI) has been hired for a period beginning on 3/15/23 and ending on 3/16/23 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (INM). To date we have now been compensated a total of one hundred and seven thousand five hundred USD via bank wire transfer to disseminate information about (INM). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and InMed Pharmaceuticals Inc., TD Media LLC has been hired for a period beginning on 04/21/2022 and ending on 06/10/2022 to publicly disseminate information about (INM:US) via digital communications. We have been paid one hundred seventy five thousand dollars USD via bank wire transfer. We own zero shares of (INM:US). [( Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net